A Phase 4 interventional study of Ranibizumab and Ranibizumab and laser in Branch Retinal Vein Occlusion, sponsored by Fukushima Medical University. Status unknown at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Fukushima Medical University · Phase 4, Interventional, and Treatment
The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.
291 studies on the registry are indexed under Retinal Vein Occlusion; 29 are open to participants now.
This study's planned enrollment of 50 is close to the median of 49 across 217 interventional studies indexed under Retinal Vein Occlusion.
Browse Retinal Vein Occlusion studies →Fukushima Medical University is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
Drug: Ranibizumab
After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
Drug: Ranibizumab and laser
Drug pages: Ranibizumab · Cycloxydim
Retinal sensitivity measured by microperimetry (MP-3, NIDEK, Japan)
Time frame: At 12 months
This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ranibizumab · Cycloxydim
Fukushima Medical University